Efficacy evidence definition from FDA expected "soon," Woodcock tells UT-Austin conference.
EFFICACY EVIDENCE DEFINITION BY FDA TO EMERGE "VERY SOON," Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the University of Texas International Industrial Pharmacy Conference in Austin, Tex. Feb. 24. CDER "has never been very explicit about what types of quality of evidence" are needed "to show efficacy," Woodcock said. An upcoming evidence guidance document "spells this out using a large number of examples." Woodcock said the document "will be particularly useful for supplemental indications, where there's a lot of extant evidence available and the question is how much additional evidence do you need." The evidence document "also pertains to...original NDA submissions," she added.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth